Home / Health / FDA Greenlights Drug for Rare Muscle Disorder
FDA Greenlights Drug for Rare Muscle Disorder
25 Sep
Summary
- FDA cleared IND for forazapadin to treat facioscapulohumeral muscular dystrophy.
- FSHD Canada Foundation to provide up to US$5 million in financing.
- Phase 2 study in FSHD is scheduled to begin in Q4 2026.
The U.S. Food and Drug Administration (FDA) has granted clearance for an Investigational New Drug (IND) application for forazapadin, a drug developed by Satellos Bioscience Inc. This clearance permits the initiation of clinical development for treating facioscapulohumeral muscular dystrophy (FSHD), a degenerative muscle disease.
This development is further supported by a significant financial commitment from the FSHD Canada Foundation, which will provide up to US$5 million in non-dilutive financing. This funding is designated for the clinical development of forazapadin specifically for FSHD.
Satellos Bioscience plans to launch a Phase 2 clinical study in FSHD patients during the fourth quarter of 2026. This study will evaluate the safety, tolerability, pharmacokinetics, and potential efficacy of forazapadin.
Forazapadin is also under investigation for Duchenne muscular dystrophy (DMD). Preliminary data from an ongoing Phase 2 trial in adults with DMD suggest a favorable safety profile and potential for muscle regeneration.
FSHD is a genetic disease affecting approximately 800,000 individuals globally, characterized by progressive muscle weakness due to abnormal activation of the DUX4 gene, with no currently approved disease-modifying therapies.
